Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.US-based biotechnology firm RXi Pharmaceuticals has closed its exclusive global license agreement for the therapeutic use of Samcyprone with Hapten Pharmaceuticals.
Subscribe to our email newsletter
As part of the deal, Hapten received a one-time upfront cash payment of $100,000 and 200,000 shares of RXi common stock.
Hapten will also be eligible to receive future milestone payments tied to the achievement of certain clinical and commercial objectives, such as first patient enrollment in a Phase III trial and regulatory approval, as well as escalating royalties based on product sales.
Samcyprone is an immunomodulating topical gel containing the active agent diphenylcyclopropenone (DPCP) developed by Hapten.
Currently, samcyprone is being evaluated in Phase IIa clinical trials to treat alopecia areata, warts and cutaneous metastases of malignant melanoma.
The proprietary gel formulation of DPCP is expected to provide an improvement in the overall safety and tolerability profile compared to treatment with DPCP as currently used.
In general, patients treated with DPCP are initially sensitized with a single high concentration of drug and subsequently treated with low non-irritant concentrations.